Molly Henderson Sells 3,678 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) CFO Molly Henderson sold 3,678 shares of the stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $4.55, for a total transaction of $16,734.90. Following the completion of the transaction, the chief financial officer now directly owns 89,868 shares in the company, valued at approximately $408,899.40. This represents a 3.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Molly Henderson also recently made the following trade(s):

• On Tuesday, January 21st, Molly Henderson sold 6,583 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $6.59, for a total value of $43,381.97.

Phathom Pharmaceuticals Price Performance

Shares of NASDAQ PHAT traded up $0.77 during mid-day trading on Friday, reaching $4.88. The company's stock had a trading volume of 1,258,108 shares, compared to its average volume of 1,006,477. Phathom Pharmaceuticals, Inc. has a 52 week low of $3.81 and a 52 week high of $19.71. The firm has a market capitalization of $339.83 million, a PE ratio of -0.86 and a beta of 0.35. The stock has a fifty day moving average of $5.45 and a two-hundred day moving average of $9.07.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on PHAT shares. HC Wainwright restated a "buy" rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. Guggenheim reaffirmed a "buy" rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, April 2nd. Cantor Fitzgerald upgraded Phathom Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, February 25th. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Wednesday. Finally, Craig Hallum reaffirmed a "buy" rating on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Phathom Pharmaceuticals currently has an average rating of "Buy" and an average price target of $22.17.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its holdings in Phathom Pharmaceuticals by 2.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 292,860 shares of the company's stock valued at $5,295,000 after buying an additional 6,990 shares during the period. FMR LLC lifted its stake in shares of Phathom Pharmaceuticals by 49,000.7% during the third quarter. FMR LLC now owns 1,304,114 shares of the company's stock worth $23,578,000 after buying an additional 1,301,458 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Phathom Pharmaceuticals by 5.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 98,025 shares of the company's stock valued at $1,772,000 after purchasing an additional 4,871 shares during the period. State Street Corp raised its position in Phathom Pharmaceuticals by 17.5% during the 3rd quarter. State Street Corp now owns 922,788 shares of the company's stock worth $16,684,000 after buying an additional 137,539 shares during the last quarter. Finally, MML Investors Services LLC lifted its stake in Phathom Pharmaceuticals by 72.8% during the 3rd quarter. MML Investors Services LLC now owns 33,860 shares of the company's stock valued at $612,000 after acquiring an additional 14,260 shares during the period. 99.01% of the stock is owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.